Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 21, 2013, Pages 6821-6830

  Kamiński, Krzysztof ^a   Obniska, Jolanta ^a   Chlebek, Iwona ^a   Wiklik, Beata ^a   Rzepka, Sabina ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

3 Phenylpyrrolidine 2,5 diones; Anticonvulsant activity; Epilepsy; In vitro studies; In vivo studies; N Mannich bases; Succinimides

Indexed keywords

1 [(4 BENZYL 1 PIPERIDYL)METHYL] 3 (2 CHLOROPHENYL) 2,5 DIONE; 1 [(4 BENZYL 1 PIPERIDYL)METHYL] 3 (2 CHLOROPHENYL)PYRROLIDINE 2,5 DIONE; 1 [(4 BENZYL 1 PIPERIDYL)METHYL] 3 (3 CHLOROPHENYL)PYRROLIDINE 2,5 DIONE; 1 [(4 BENZYL 1 PIPERIDYL)METHYL] 3 (4 CHLOROPHENYL)PYRROLIDINE 2,5 DIONE; 1 [(4 BENZYL 1 PIPERIDYL)METHYL] 3 PHENYLPYRROLIDINE 2,5 DIONE; 1 [(4 YCLOHEXYLPIPERAZIN 1 YL)METHYL]PYRROLIDINE 2,5 DIONE; 1 MORPHOLINOMETHYL 3 PHENYLPYRROLIDINE 2,5 DIONE; 3 (2 CHLOROPHENYL 1 MORPHOLINOMETHYL)PYRROLIDINE 2,5 DIONE; 3 (2 CHLOROPHENYL); 3 (2 CHLOROPHENYL) 1 [(4 CYCLOHEXYLPIPERAZIN 1 YL)METHYL]PYRROLIDINE 2,5 DIONE; 3 (2 CHLOROPHENYL) 1 [(4 PYRIMIDIN 2 YLPIPERAZIN 1 YL)METHYL]PYRROLIDINE 2,5 DIONE; 3 (3 CHLOROPHENYL); 3 (3 CHLOROPHENYL) 1 (MORPHOLINOMETHYL)PYRROLIDINE 2,5 DIONE; 3 (3 CHLOROPHENYL) 1 [(4 CYCLOHEXYLPIPERAZIN 1 YL)METHYL]PYRROLIDINE 2,5 DIONE; 3 (4 CHLOROPHENYL)PYRROLIDINE 2,5 DIONE DERIVATIVE; 3 PHENYL 1 [[4 (PYRIMIDIN 2 YL)PIPERAZIN 1 YL]METHYL]PYRROLIDINE 2,5 DIONE; 3 PHENYL DERIVATIVE; 3 PHENYLPYRROLIDINE 2,5 DIONE DERIVATIVE; ANTICONVULSIVE AGENT; CYTOCHROME P450 3A4; ETHOSUXIMIDE; ETIRACETAM; FORMALDEHYDE; MANNICH BASE; PENTETRAZOLE; PHENYTOIN; PILOCARPINE; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; EPILEPTIC STATE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROTOXICITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TONIC CLONIC SEIZURE; TOXICITY TESTING;

ANIMALIA; MUS; RATTUS;

3-PHENYLPYRROLIDINE-2,5-DIONES; ANTICONVULSANT ACTIVITY; EPILEPSY; IN VITRO STUDIES; IN VIVO STUDIES; N-MANNICH BASES; SUCCINIMIDES;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; CYTOCHROME P-450 CYP3A; DISEASE MODELS, ANIMAL; DRUG DESIGN; ELECTROSHOCK; HUMANS; MALE; MANNICH BASES; MICE; MICROSOMES, LIVER; MOTOR ACTIVITY; PENTYLENETETRAZOLE; PROTEIN BINDING; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885180799     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.07.029     Document Type: Article

References (31)

1. World Health Organization, Epilepsy: Key facts. Available at: www.who.int/mediacentre/factsheets/fs999/en.
2. Epilepsy Foundation: About Epilepsy. Available at: www. epilepsyfoundation.org/about/statistics.cfm.
3. W. Löscher, and D. Schmidt Epilepsy Res. 69 2006 183
4. J.A. Cramer, S. Mintzer, J. Wheless, and R.H. Mattson Expert Rev. Neurother. 10 2010 885
5. J.R. Pollard, and J. French Lancet Neurol. 5 2006 1064
6. H.N. Khan, S. Kulsoom, and H. Rashid Epilepsy Res. 98 2012 62
7. M.G. Wong, J.A. Defina, and P.R. Andrews J. Med. Chem. 29 1986 562
8. N. Siddiqui, W. Ahsan, M.S. Alam, R. Ali, and K. Srivastava Arch. Pharm. Chem. Life Sci. 345 2012 185
9. K. Kamiński, J. Obniska, B. Wiklik, and D. Atamanyuk Eur. J. Med. Chem. 46 2012 4634
10. K. Kamiński, S. Rzepka, and J. Obniska Bioorg. Med. Chem. Lett. 21 2011 5800
11. K. Kamiński, and J. Obniska Bioorg. Med. Chem. 16 2008 4921
12. K. Kamiński, J. Obniska, and M. Dybała Eur. J. Med. Chem. 43 2008 53
13. J. Obniska, K. Kamiński, D. Skrzyńska, and J. Pichór Eur. J. Med. Chem. 44 2009 2224
14. J. Obniska, H. Byrtus, K. Kamiński, M. Pawłowski, M. Szczesio, and J. Karolak-Wojciechowska Bioorg. Med. Chem. 18 2010 6134
15. J. Obniska, M. Kopytko, A. Zagórska, I. Chlebek, and K. Kamiński Arch. Pharm. Chem. Life Sci. 343 2010 333
16. J. Obniska, and A. Zagórska Il Farmaco 58 2003 1227
17. C.A. Miller, and L.M. Long J. Am. Chem. Soc. 73 1951 4895
18. J. Obniska, K. Kulig, and A. Zejc Acta Pol. Pharm. Drug Res. 55 1998 223
19. S.H. White, J.H. Woodhead, K.S. Wilcox, J.P. Stables, H.J. Kupferberg, and H.H. Wolf Discovery and Preclinical Development of Antiepileptic Drugs R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca, Antiepileptic Drugs 5th ed. 2002 Lippincott Williams and Wilkins Philadelphia 36 48
20. M.E. Barton, B.D. Klein, H.H. Wolf, and H.S. White Epilepsy Res. 47 2001 217
21. USFDA Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling, U.S. Food and Drug Administration Publication, 2006.
22. H.S. White Epilepsia 44 2003 2
23. R.L. Krall, J.K. Penry, B.G. White, H.J. Kupferberg, and E.A. Swinyard Epilepsia 19 1978 409
24. H.J. Kupferberg Epilepsia 30 1989 51
25. N.W. Dunham, and T.A. Miya J. Am. Pharm. Assoc. Sci. 46 1957 208
26. W.C. Brown, D.O. Schiffman, E.A. Swinyard, and L.S. Goodman J. Pharmacol. Exp. Ther. 107 1953 273
27. R.F. Kaminski, M.R. Livingood, and M.A. Rogawski Epilepsia 45 2004 864
28. R.J. Racine Electroencephalogr. Clin. Neurophysiol. 32 1972 281
29. R.L. Walsky, and R.S. Obach Drug Metab. Dispos. 32 2004 647
30. R. Thirumurugan, D. Sriram, A. Saxena, J. Stables, and P. Yogeeswari Bioorg. Med. Chem. 14 2006 3106
31. P. Yogeeswari, D. Sriram, R. Thirumurugan, J. Raghavendran, K. Sudhan, P. Pavana, and J. Stables J. Med. Chem. 48 2005 6202